Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- (-) Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- (-) Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- (-) Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- (-) Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Audience
Display Only
Showing 84 Results
A Precision Paradigm for Value Assessment: How Frameworks Can Account for Personalized Medicine to Inform Payers, Providers, Innovators and Patients
Personalized Medicine Coalition Senior Vice President of Science Policy Daryl Pritchard, PhD, explores personalized medicine and value assessment frameworks.
Where Are They Now: Checking In With Former NPC Intern Jan Hansen
Jan Hansen, PhD, currently Vice President, Evidence for Access Medical Unit, US Medical Affairs at Genentech, participated in NPC’s pharmaceutical internship program in 1982. Dr. Hansen chatted with…
Considerations When Using ICER's Value Assessments
This week we read with great interest an article posted on the Health Affairs Blog that directly responded to National Pharmaceutical Council Chief Science Officer Dr. Robert Dubois’ Sept. 17…
Why the VA Should Proceed with Caution on ICER Collaboration
In a new blog published by Health Affairs, NPC Chief Science Officer and Executive Vice President Robert W. Dubois, MD, PhD, expands on our initial thoughts on the collaboration between the Institute…
What Kinds of Information Do Payers and Providers Want for Decision-Making?
A new white paper from Xcenda/AmerisourceBergen and NPC highlights survey findings from payers and providers on what types of evidence are most important to them when it comes to making population…
Will Value Assessment Frameworks Promote Health Value and Access for Veterans?
NPC expressed concerns about the partnership between the Institute for Clinical and Economic Review and the U.S. Department of Veterans Affairs Pharmacy Benefits Management Services office to…
CER Collaborative Helps Health Care Decision-Makers Assess Evidence
A feature article in this month's Value and Outcomes Spotlight highlights the importance of comparative effectiveness research (CER) and details the CER Collaborative Initiative, a joint effort by…
NPC Evaluates ICER’s Revised Value Assessment Framework
The Institute for Clinical and Economic Review (ICER) today released its revised value assessment framework, which included a number of changes reflected in NPC's extensive public comments, but NPC…
NPC @ AcademyHealth Annual Research Meeting: What Do We Know about High-Deductible Health Plans?
NCP Health Policy Fellow Ilene L. Hollin, PhD, MPH, will moderate a panel, “What Do We Know about High-Deductible Health Plans and What Do We Need to Learn?” to discuss what we know – and don’t know …
NPC @ DIA 2017 Annual Meeting: Exploring Comparative Effectiveness Research
NPC Chief Science Officer and Executive Vice President Robert Dubois, MD, PhD, will address how comparative effectiveness research is being used by health care decision-makers at the Drug Information…
Why Value Framework Assessments Arrive at Different Conclusions
New peer-reviewed research from the National Pharmaceutical Council (NPC) found inconsistencies in how four value frameworks assessed multiple myeloma treatments.
National Eczema Association Weighs In on Value Frameworks
NPC President Dan Leonard recently sat down for a conversation with Julie Block, President and CEO of the National Eczema Association, to discuss atopic dermatitis (AD) and value assessment…
How Are Health Plans Using Patient Data to Improve Outcomes?
Health plans collect enormous amounts of data through electronic health records, administrative claims, mobile health devices and other sources. Is the data simply sitting on a shelf, or is it being…
NPC Submits Comments to FDA on Exchange of Clinical and Economic Information
To achieve our shared goal of a high-performing, value-based health care system, informed and evidence-based decisions are needed. Greater efficiency and better care requires more information…
NPC Outlines Needed Improvements to ICER's Revised Value Assessment Framework
NPC submitted comments to the Institute for Clinical and Economic Review (ICER), offering constructive suggestions on ways to further improve its revised value assessment framework.
Workshop Looks “Under the Hood” of Value Assessment Frameworks
During the Feb. 27 interactive workshop, “Understanding the Strengths and Limitations of Value Assessment Frameworks,” hosted by the National Pharmaceutical Council and PhRMA, health care…
NPC President Dan Leonard Offers Perspectives on Health Reform
In a commentary recently published in The American Journal of Pharmacy Benefits, NPC President Dan Leonard offered 10 key considerations for stakeholders as they navigate health reform discussions.
FDA Releases Guidance Documents on Communicating Clinical and Economic Information
The Food and Drug Administration (FDA) this week has released a series of draft guidance documents that clarify how and when different types of clinical and economic information may be communicated.